trial

Antipsychotic Induced Structural and Functional Brain Changes

NCTId NCT02435095
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Terminated
Enrollment 174 (actual)
Sponsored by RWTH Aachen University
Primary completion 2020-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Terminated
Enrollment
174 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2015-05
Primary completion
2020-08
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
AripiprazoleIntermittent treatment

Sponsors

RWTH Aachen UniversityLead Sponsor

Investigators

1
Klaus Mathiak, Univ.-Prof. Dr. Dr.Principal Investigator

Sites

11 total
Aachen, GermanyAachen, GermanyAachen, GermanyBonn, GermanyDüren, GermanyDüsseldorf, GermanyEssen, GermanyGangelt, GermanyKrefeld, GermanyLangenfeld, GermanyViersen, Germany

Facts & assertions

4 sourced
Enrollment
174
Phase
PHASE4
Primary Completion Date
2020-08
Status
TERMINATED
relationships
The graph out of here
drug
Aripiprazole
drug
Intermittent treatment
drug
lead_sponsor
RWTH Aachen University
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Klaus Mathiak, Univ.-Prof. Dr. Dr.
person